News

Use of efruxifermin did not result in a significant reduction in fibrosis without worsening of MASH at week 36 compared with placebo in the phase 2b SYMMETRY trial.

These findings support the conclusion that switching between adalimumab biosimilars largely maintains efficacy for patients with psoriasis.

Discover an approach to diagnosing food sensitivities, offering personalized diets and significant symptom relief through testing methods.

Ixo-vec, a potential one shot therapy for age-related macular degeneration has achieved noninferior results in maintaining best-corrected visual acuity and central subfield thickness.

Evolocumab reshapes arterial plaque, reducing cardiovascular risk by lowering microcalcification and shifting plaque composition over 18 months.

Notable psychosocial and occupational burdens, as well as impairments to emotional well-being, were seen among caregivers of adolescents with alopecia.

New research reveals older adults face higher anaphylaxis risks from medications and IV contrast, often presenting with severe symptoms and outcomes.

Findings suggest sleep disorders are common in PBC and are linked to worse biochemical markers, greater symptom burden, and reduced treatment response rates.

Recent research uncovers how lifestyle and environmental factors influence the incidence of IgAN and membranous nephropathy.

MAR001 significantly lowers remnant cholesterol and triglycerides in Phase 2a data, offering hope for high-risk cardiovascular patients.

Najy Issa, MD, describes “underwhelming” universal HBV screening uptake since 2023 CDC guidelines were implemented and steps to get more patients screened.

Data released by Cognition Therapeutics shows that oral zervimesine resulted in substantially reduced lesion growth over 18 months compared to placebo.

Horst explains the importance of addressing depression and anxiety in patients with IBD and steps clinicians can take to support their patients’ mental health.

In this interview, Raj Chovatiya, MD, PhD, describes roflumilast cream's success in addressing unmet needs for atopic dermatitis.

A recent study reveals that anaphylaxis rates remain stable during the COVID-19 pandemic, despite reduced emergency visits.

A post hoc analysis of trial data reveals the effects of intraretinal fluid on best-corrected visual acuity in patients after port delivery system treatment for nAMD.

In this episode, hosts explore updates on continuous glucose monitoring (CGM) systems from April 2025.

These phase 3 findings from the ARRECTOR trial, published in JAMA, demonstrate rapid and significant relief from plaque psoriasis with roflumilast foam use.

In a recent review, experts answer frequent questions allergists have about conducting proximity challenges in patients with food allergy anxiety.

Symptoms of immunoglobulin A nephropathy were reduced substantially during the 1-month follow-up period.

A recent study reveals that asthma-COPD overlap does not significantly worsen outcomes in well-managed severe asthma patients.

NewAmsterdam Pharma announces promising Phase 3 results for obicetrapib, showing significant LDL-C reduction in patients with ASCVD and/or HeFH.

The asthma-related emergency department visits highlighted here, following the Canadian wildfires near Ontario, were attributed to smoke inhalation.

Patients with hereditary angioedema experience high adherence and persistence rates with berotralstat, lanadelumab, and SC-pdC1-INH for long-term prophylaxis.

XGBoost displayed a high rate of accuracy, sensitivity, and precision, indicating its effectiveness at highlighting depressive symptoms before diagnosis.

New findings reveal that higher HbA1c levels worsen asthma control in children, linking metabolic dysfunction to increased asthma morbidity.

EBX-102-02 was well tolerated and led to clinically meaningful improvements across multiple symptom domains in patients with IBS-C.

These data suggest that heart health, as determined by the LC9 assessment, is positively correlated with pulmonary health.